November 27, 2006

Merlion Article in Nature - "Rising Biotech Appetite in the East"

The tripartite deal in which a Singaporean company, MerLion Pharmaceuticals, acquired two European biotechs last August is an indication of both the growing maturity of the biotech industry in Asia and of the ongoing globalization of the industry as a whole. An accompanying round of financing and a planned initial public offering (IPO) will rapidly accelerate MerLion’s growth and could also offer other emerging companies in the region a possible development model. However, there is no immediate evidence that others are, as yet, ready to follow MerLion’s lead.
PDF Download

read more »

October 30, 2006

NovImmune raises CHF 58 million in Series B Private Financing

NovImmune SA (“NovImmune”), a Genevabased drug development company focusing on immune mechanisms to clinically impact immune-related diseases,  inflammation and organ transplantation, announced today the closing of a CHF 58 million (ca. USD 46 million, EUR 37 million) Series B private financing round. The round was led by a new investor, BZ Bank, representing several of its clients, and was also supported by another new investor, Pictet Private Equity Investors SA. Existing investors including Lombard Odier Darier Hentsch, Novartis Venture Fund and Aravis Venture also participated.
PDF Download

read more »

September 26, 2006

ENTREMED COMMENCES MKC-1 CLINICAL TRIAL IN LEUKEMIA PATIENTS

EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced commencement of a Phase 1 study with its clinical-stage drug candidate, MKC-1, in patients with hematological (blood) malignancies. The study will be conducted at the University of Texas MD Anderson Cancer Center in Houston, Texas. Francis J. Giles, M.D., Professor, Department of Leukemia at the MD Anderson Cancer Center, will serve as Principal Investigator. MKC-1 is also being evaluated currently in a Phase 2 clinical study in patients with metastatic breast cancer.
PDF Download

read more »

September 12, 2006

Omeros Acquires Nura

Omeros Corporation, a Seattle-based biopharmaceutical company, announced today that it has acquired Nura, Inc., a company developing treatments for pain and other central nervous system disorders including schizophrenia and Parkinson's disease. As part of the transaction, the premier venture firms of ARCH Venture Partners, Aravis Venture and Novartis Venture Funds made a substantial investment in Omeros. The acquisition expands and enhances the research capabilities and development of current and future products for Omeros, which is advancing a pipeline of pharmaceuticals and delivery systems for use in orthopedics, rheumatology, urology, cardiovascular medicine, general surgery and pain management.
PDF Download

read more »

August 21, 2006

MerLion Pharmaceuticals Announces the completion of a merger with Combinature Biopharm AG and Athelas SA and first closure of a US$30M financing round

MerLion Pharmaceuticals Pte Ltd (MerLion) of Singapore, the world’s leading natural products based drug discovery company, announces that it has completed a merger by exchange of shares with Combinature Biopharm AG (Berlin, Germany) and Athelas SA (Geneva, Switzerland). Both European companies become 100% subsidiaries of MerLion whose headquarters and drug discovery research centre is based in Singapore. Drug development of its anti infective programmes and nuclear magnetic resonance screening activities will be conducted from Berlin.
PDF Download

read more »

July 24, 2006

Ambrx Secures Additional $3 Million in Series C Financing

Ambrx, Inc., announced today it has secured commitments for an additional $3 million in Series C financing. This further investment, which was provided by Scottish Widows Investment Partnership, brings the total secured in the Company’s Series C financing to $55 million. Net proceeds will be used to further expand Ambrx’s novel protein modification platform, support the development of its product pipeline and for general working capital purposes.
PDF Download

read more »

July 05, 2006

Ambrx Secures $52 Million in Series C Financing

Ambrx, Inc., announced today it has secured commitments for $52 million in Series C financing from a broad, international syndicate of new and existing investors. Net proceeds will be used to further expand Ambrx’s novel protein modification platform, support the development of its product pipeline and for general working capital purposes.
PDF Download

read more »

May 31, 2006

MERLION PHARMA AND ICES INK R&D PARTNERSHIP TO BOOST SINGAPORE S BIO-TECHNOLOGY INDUSTRY

The Institute of Chemical and Engineering Sciences (ICES), a research institute under the Agency for Science, Technology and Research, signed a research collaboration agreement with MerLion Pharmaceuticals Pte Ltd to synthesise and develop novel molecules, based upon naturally derived compounds, for anti-tumour drug therapies. The agreement was signed by Dr Tony Buss, President and CEO of MerLion and Dr Keith Carpenter, Executive Director of ICES.
PDF Download

read more »

May 15, 2006

ENTREMED INITIATES COMBINATION PHASE 2 CLINICAL TRIAL WITH PANZEM® NCD IN CARCINOID CANCER

EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has commenced a Phase 2 clinical trial to evaluate the safety and efficacy of its lead clinical-stage drug candidate, Panzem® NCD, in combination with Avastin® (bevacizumab) in patients with locally advanced or metastatic carcinoid tumors. The study will be coordinated by Boston’s Dana-Farber/Partners Cancer Care (DFPCC), a collaboration among The Brigham and Women’s Hospital, Inc., Dana-Farber Cancer Institute, Massachusetts General Hospital, and the Beth Israel Deaconess Medical Center (BIDMC). The study sites include the Dana Farber Cancer Institute, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center and will be conducted under the direction of Matthew Kulke, M.D. as principal investigator.
PDF Download

read more »

April 25, 2006

PANOMICS ANNOUNCES FORMATION OF NEW EUROPEAN SUBSIDIARY

Panomics, Inc., developer of innovative products and technologies for Parallel Quantitative Biology (PQB) TM, and leading provider of life sciences research reagents, today announced the opening of a wholly owned European subsidiary, Panomics SRL, located in Milan, Italy. Mr. Luigi Pirovano has been appointed the subsidiary’s Managing Director reporting to George Bers, Executive Vice President for Commercial Operations.
PDF Download

read more »

March 02, 2006

MerLion Pharmaceuticals Pte Ltd Receives Frost & Sullivan Market Penetration Leadership Award

The 2005 Frost & Sullivan Market Penetration Leadership Award for the Asia Pacific drug discovery markets is presented to Singapore-based MerLion Pharmaceuticals Pte Ltd.. The company has been selected for this award based on its high-growth, novel solutions in high throughput screening (HTS), chemical analysis and lead optimisation.
PDF Download

read more »